Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance

Cytek Biosciences, Inc.

2022-Q1 EPS reported $0.02 revenue$35,064,000

Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.
GAAP net loss of $2.2M vs net income of $0.1M last year; operating loss $2.4M vs income $1.1M.
Adjusted EBITDA $1.9M, up from $1.1M; adjusted gross margin 61% vs 60%.
FY2022 revenue guidance raised to high end of $160M-$168M range.
Service revenue more than doubled from prior year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.